期刊文献+

人乳头瘤病毒预防性疫苗的研究进展 被引量:1

Human Papilloma Virus Prophylactic Vaccine Research Progress
下载PDF
导出
摘要 20世纪80年代初德国病毒学家Harald Zur Hausen首次提出人乳头瘤病毒(Human papillomavirus)感染与宫颈癌密切相关的假设,此后国内外大量的证据使得人们对子宫颈癌和HPV的因果关联达成了共识,即HPV感染是子宫颈癌的必然病因。这一发现不但促进了基于HPVDNA检测子宫颈癌新筛查技术的发展,同时也研发成功第一种癌症预防性疫苗,即HPV预防性宫颈癌疫苗。 Objective:In 1980s,Germany virologist——Harald Zur Hausen firstly raise the hypotheses that human papilloma virus(HPV) infection closely related to cervical cancer.Afterwards,lots of evidence proved the causal relationship between persistent HPV infection and cervical cancer,and made a conclusion that HPV infection is the necessary cause of cervical cancer.This discovery is marked as a milestone in cervical cancer prevention,which not only promotes the development of HPV DNA-based cervical cancer screening technology,but also guides the development of HPV prophylactic vaccine for cervical cancer.This review states the latest researches of HPV vaccine.
出处 《内蒙古医学杂志》 2012年第7期828-831,773,共5页 Inner Mongolia Medical Journal
关键词 人乳头瘤病毒 宫颈癌 疫苗 Human papilloma virus Cervical cancer Vaccine
  • 相关文献

参考文献20

  • 1Shi JF, Qiao YL, Smith JS, et al. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia[J]. Vaccine, 2008, 19(26) : 53 - 9.
  • 2Burchell AN, Winer RL, de Sanjos S, et al. Epidemiology and transmission dynamics of genital HPV infection [ J ]. Vaccine,2006, 24(3) :52- 61.
  • 3Parkin DM, Bray F. The burden of HPV- related cancers[J]. Vaccine, 2006, 31(24) : 11 - 25.
  • 4Walboomers JM, Jacobs MV, Manos MM, et al. Human papillo- mavirus is a necessary cause of invasive cervical cancer worldwide [J].J Pathol, 1999, 189(1):12.
  • 5Chen W , Zhang X , Molijin A , et al. Human papillomavirus type - distribution in cervical in china: The importance of HPV 16 and 18[J]. Cancer Causes Control, 2009, 20(9) : 1 705.
  • 6赵方辉,乔友林.人乳头瘤病毒预防性疫苗的研究进展及应用前景[J].中华预防医学杂志,2009,43(7):640-643. 被引量:5
  • 7XG Jia. Reproductive Tract Infection and Reprodueive Health in Chinese Women[J]. China Maternal and Child Health, 1997, 12 (1):49- 51.
  • 8LQ Yah. Epidemiology and Risk factors for lower Reproductive Tract infection in Women living in Lu Liang community of Chengjiang[J]. Modem Preventive Medicine, 1997,24:3.
  • 9LH Wang, GL Zhao, LJ Chen, et al. A prevalence survey of pro- ductive tract infection in married women [ J ]. Chinese Journal of Epidemiology, 2000, 21:464.
  • 10CG Shao. Prevention and Treatment of STD and its Stxategy in China[J]. Chinese Journal of Dermatology, 1993, 26 : 131 - 133.

二级参考文献108

  • 1赵恩锋,鲍嫘,李超,宋磊,李亚里.近50年宫颈癌的发病趋势和临床特点分析[J].解放军医学杂志,2005,30(7):644-646. 被引量:47
  • 2乔友林.子宫颈癌预防研究的里程碑[J].基础医学与临床,2006,26(12):1293-1295. 被引量:22
  • 3李连弟,鲁凤珠,张思维,牧人,孙秀娣,皇甫小梅,孙杰,周有尚,欧阳宁慧,饶克勤,陈育德,孙爱明,薛志福,夏毅.中国恶性肿瘤死亡率20年变化趋势和近期预测分析[J].中华肿瘤杂志,1997,19(1):3-9. 被引量:869
  • 4Christopherson WM, Lundin FE Jr, Mendez WM, et al. Cervical cancer control: a study of morbidly and mortality trends over a twenty-one-year period. Cancer, 1976, 38 : 1357-1366.
  • 5Gissmann L, deVilliers EM, zur Hausen H. Analysis of human genital warts (condylomata acuminata) and other genital tumors for human papillomavirus type 6 DNA. Int J Cancer, 1982, 29: 143-146.
  • 6Villa LL, Costa RL, Petta CA, et aL High sustained efficacy of a prophylactic quadfivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer, 2006,95 : 1459-1466.
  • 7Joura EA, Leodolter S, Hemandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet, 2007, 369:1693-1702.
  • 8Tay EH, Garland S, Tang G, et al. Clinical trial experience with prophylactic HPV 6/11/16/18 VLP vaccine in young women from the Asia-Pacific regiotr Int J Gynaecol Obstet, 2008, 102: 275 -283.
  • 9Harper DM. Impact of vaccination with Cervarix ( trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Gynecol Oncol, 2008, 110 ( 3 Suppl 1 ) : S11-17.
  • 10Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin , In press 2009.

共引文献103

同被引文献26

  • 1乔友林.中国妇女人乳头瘤病毒感染和子宫颈癌的流行病学研究现状及其疫苗预防前景[J].中华流行病学杂志,2007,28(10):937-940. 被引量:92
  • 2Walboomers JM,Jacobs MV,Manos MM,et al.Human papillomavirus is a necessary cause of invasive cervical cancer worldwide[J].J Pathol,1999,189:12-19.
  • 3Woodman CB,Collins S,Winter H,et al.Natural history of cervical human papillomavirus infection in young women:a longitudinal cohort study[J].Lancet,2001,357:1831-1836.
  • 4Paavonen J,Naud P,Salmerón J,et al.Efficacy of human papillomavirus(HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types(PATRICIA):final analysis of a double-blind,randomized study in young women[J].Lancet,2009,374:301-314.
  • 5Jin XW,Lipold L,Sikon A,et al.Human papillomavirus vaccine:safe,effective,underused[J].Cleve Clin J Med,2013,80:49-60.
  • 6af Geijersstam V,Kibur M,Wang Z,et al.Stability over time of serum antibody levels to human papillomavirus type 16[J].J Infect Dis,1998,177:1710-1714.
  • 7Safaeian M,Porras C,Schiffman M,et al.Epidemiological study of anti-HPV16/1 8 seropositivity and subsequent risk of HPV16 and-18 infections[J].J Natl Cancer Inst,2010,102:1653-1662.
  • 8De Carvalho N,Teixeira J,Roteli-Martins CM,et al.Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women[J].Vaccine,2010,28:6247-6255.
  • 9Stanley M.HPV-immune response to infection and vaccination[J].Infect Agent Cancer,2010,5:19.
  • 10Smith JF,Brownlow M,Brown M,et al.Antibodies from women immunized with Gardasil cross-neutralize HPV 45 psedovirions[J].Hum Vaccin,2007,3:109-115.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部